Table 2. Adjuvant treatment characteristics and irAEs ≥grade 2.
| Characteristic (N=222) | N (%) |
|---|---|
| Type of adjuvant therapy | |
| Nivolumab | 135 (61) |
| Pembrolizumab | 62 (28) |
| Dabrafenib+trametinib | 15 (7) |
| Other* | 10 (4) |
| Treatment duration | N=219 |
| Median, months (range) | 9.5 (0.0–35.0) |
| irAEs ≥grade 2, any | 94 (42) |
| Endocrine | |
| Thyroid dysfunction | 23 (10) |
| Adrenal insufficiency | 15 (7) |
| Gastrointestinal | |
| Colitis | 14 (6) |
| Hepatitis | 4 (2) |
| Pulmonary | |
| Pneumonitis | 10 (4) |
| Dermatologic | |
| Skin rash/psoriasis | 11 (5) |
| Bullous dermatitis | 4 (2) |
| Cardiac | |
| Myocarditis† | 5 (2) |
| Musculoskeletal | |
| Myositis | 4 (2) |
| Other (each <2%) | ‡ |
All percentages are calculated on the total treated population (N=222). irAE counts reflect cumulative events across all toxicity episodes per patient.
*
Other includes: clinical trial agent (BMSCA2098FC), dabrafenib monotherapy, vemurafenib, ipilimumab+nivolumab, pembrolizumab+mRNA-4157.
†
One patient had fatal (grade 5) myocarditis.
‡
Includes fatigue, fever, hepatitis, myasthenia gravis, nephritis, peripheral neuropathy, thrombocytopenia, thrombosis, encephalitis, esophagitis, arthritis, gastritis, sarcoidosis.
irAE, immune-related adverse event.